Ropeginterferon alfa-2b is named as an intervention in 3 current clinical trials in our China and USA registers. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is PharmaEssentia. The most-studied condition is Primary Myelofibrosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086 · ClinicalTrials.gov ↗ · Essential Thrombocythemia
|
Phase 3 | Active, closed | PharmaEssentia | USA, China |
|
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033 · ClinicalTrials.gov ↗ · Primary Myelofibrosis, Myeloproliferative Neoplasm
|
Phase 3 | Active, closed | PharmaEssentia | USA, China |
|
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948 · ClinicalTrials.gov ↗ · Polycythemia Vera
|
Phase 2 | Active, closed | PharmaEssentia | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Ropeginterferon alfa-2b on the HPRA medicines list.
No entry for Ropeginterferon alfa-2b in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| PharmaEssentia | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name Ropeginterferon alfa-2b as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is PharmaEssentia. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Ropeginterferon alfa-2b, for example Besremi 250 micogram/0.5 ml Solution for injection in pre-filled pen (Aop Orphan Pharmaceuticals GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Ropeginterferon alfa-2b has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ropeginterferon alfa-2b works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ropeginterferon alfa-2b works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ropeginterferon alfa-2b (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.